FONAR Corporation (FONR) Company Overview

What does FONAR do—and is FONR still a public stock?

FONAR Corporation combines two activities: designing and servicing magnetic resonance imaging systems, and managing diagnostic-imaging centers. Incorporated in Delaware in 1978, it evolved from an MRI pioneer into a hybrid equipment and healthcare-services company.

How the two-part operating model works

The medical-equipment segment sells, upgrades and services scanners, especially the Upright Multi-Position MRI. Health Management Corporation of America, or HMCA, supplies billing, collections, credentialing, contracting, compliance, IT, staffing, equipment and other non-medical infrastructure. It also owns six Florida imaging facilities. The FY2025 Form 10-K describes this two-segment structure and the operating responsibilities of HMCA.

What changed on June 3, 2026?

FONR is no longer publicly traded. A June 3, 2026 merger left FONAR Corporation wholly owned by FONAR, LLC; Nasdaq trading was suspended and delisting was requested. The merger-completion Form 8-K is the definitive source for the change in status.

How does FONAR make money?

FONAR’s economic engine was not new scanner sales. By FY2025, recurring HMCA management fees, patient fees and service work made it primarily a regional imaging-services operator with proprietary equipment expertise.

Which revenue streams are recurring?

HMCA agreements generally use flat monthly fees, which ranged from about $70,358 to $459,544 in FY2025. The structure adds visibility but can create receivables when clients collect slowly. Service work is recurring; scanner sales are episodic capital purchases.

Which segment really carries profitability?

The concentration is even clearer in profit. In FY2025, management generated $19.205M of segment operating income while equipment lost $7.606M. Proprietary MRI technology differentiated FONAR, but managed centers produced the profit and funded the smaller equipment franchise.

What did FONAR’s latest reported period show?

The final full public quarter ended March 31, 2026. Revenue was stable, but faster cost growth reduced profit and cash generation amid merger, IT, cybersecurity and repair-expansion spending.

What changed in the March 2026 quarter?

The March 2026 Form 10-Q provides the latest detailed public income statement, balance sheet, cash-flow statement and segment commentary.

What did nine-month scan volume and cash flow reveal?

For nine-month FY2026, revenue rose 1.3% to $78.062M, but operating income fell 19.3% to $8.638M as costs reached $69.424M. Scans increased 3.0% to 165,612. Higher volume alongside lower patient-fee revenue shows why reimbursement quality matters as much as scan count.

Operating cash flow fell to $3.440M from $7.045M. After $2.435M of capex, simple free cash flow was about $1.005M. A $5.352M receivables increase made collections the key cash-flow issue.

How financially strong was FONAR before the take-private deal?

FONAR entered the merger with strong liquidity and little conventional funded debt. Acquisition financing then introduced secured bank facilities, so the pre-merger balance sheet cannot be carried forward unchanged.

Why liquidity looked stronger than earnings momentum

What does the cash-flow conversion say?

FY2025 revenue was $104.351M, net income $10.673M and operating cash flow $11.265M. After $3.792M of capex, simple free cash flow was about $7.473M. Nine-month FY2026 free cash flow near $1.005M showed how receivable growth can absorb cash.

At closing, FONAR and its parent obtained a $20M term facility and $15M revolver from OceanFirst Bank, secured by substantially all borrower and guarantor assets. Draws, interest and covenants now matter to private-company analysis.

Which turning points shaped FONAR’s strategy?

FONAR migrated from MRI invention and equipment commercialization to a recurring imaging-services platform. That shift explains why management and diagnostic services eventually produced more than 90% of revenue.

1. 1977
   FONAR’s founders built an early whole-body MRI scanner, establishing the technical foundation for the company’s equipment identity.
2. 1978–1981
   The company incorporated in 1978, introduced its first commercial MRI scanner in 1980 and became public in 1981, funding commercialization and an installed base.
3. 1982
   FONAR introduced an iron-core open MRI concept, moving away from the enclosed geometry associated with conventional systems.
4. 1996
   The Stand-Up, later branded Upright, MRI extended the product proposition to weight-bearing and position-dependent imaging.
5. 1997
   HMCA was formed, creating the organizational vehicle for management services and recurring center economics.
6. 2013–2015
   HMCA acquired majority ownership of Health Diagnostics Management and integrated it, expanding the New York and Florida operating platform.
7. 2023
   FONAR became an exclusive distributor of SwiftMR to its customers, adding software intended to improve image quality and shorten scans.
8. 2025–2026
   A management-affiliated take-private process culminated in the June 2026 merger, ending public trading and changing the capital structure.

Why the move from scanner sales to center management mattered

The transition reduced dependence on infrequent scanner orders. Monthly management fees and patient revenue recur from the same equipment footprint, explaining why HMCA became the profit center and why scans, collections and reimbursement matter more than unit shipments.

The official FONAR timeline documents the technological milestones. The strategic lesson is that FONAR built a service business to monetize imaging demand when equipment economics alone were insufficient.

What gives FONAR a competitive advantage—and where is the moat weaker?

FONAR’s strongest differentiation is Upright MRI imaging while patients sit, stand, bend or lie down. Its magnet geometry and rotating bed enable weight-bearing and flexion-extension studies. The company’s Upright MRI product page explains the positional capability and scanner configuration.

Upright imaging and installed-base know-how

A specialized scanner creates a niche for weight-bearing or position-dependent imaging. Field-service knowledge and the installed base support repair, upgrades and software revenue. In November 2023, FONAR announced exclusive SwiftMR distribution for its customers; the official SwiftMR announcement described FDA-cleared denoising and sharpening software designed to enable scan-time reductions of up to 50%.

The managed-center operating loop

HMCA’s advantage is operational. Billing, credentialing, payor contracting, scheduling, compliance, staffing and maintenance form a reusable platform that can create modest scale economies and switching friction.

The weak point is that the equipment segment remained loss-making. Research and development of $1.576M in FY2025 equaled 17.6% of equipment-segment revenue, yet product sales were only $0.563M. The technology can support differentiation and service revenue without necessarily producing enough new-system volume to cover the full cost base.

Who competed with FONAR, and what shaped market position?

FONAR faced global equipment manufacturers and local imaging providers. The first competed through product breadth and research scale; the second through referrals, location, payor access and scheduling.

Equipment competition is global

Large rivals spread research and commercial costs across many models and geographies. FONAR’s task is to defend positional-imaging use cases and monetize service and upgrades. The filing said named rivals lacked an open upright MRI, but conventional systems remain substitutes.

Imaging-service competition is local and payor-driven

Physicians influence referrals, insurers set reimbursement and patients value convenience. Local execution—authorizations, denials, utilization and collections—therefore matters more than national brand scale.

Who owned and controlled FONAR before the merger?

FONAR combined dispersed common ownership with super-voting shares: one vote for common, ten for Class B and twenty-five for Class C. Class C therefore carried influence far beyond its share count.

How multi-class voting shaped control

The structure let institutions own meaningful economic stakes while insiders retained disproportionate voting influence, framing the conflicts reviewed by the merger special committee.

What going private changed

At the May 28, 2026 special meeting, holders cast 13,124,769 votes for the merger, 551,079 against and 17,171 abstentions. Among disinterested shares, 3,279,090 votes favored the merger, 551,079 opposed it and 17,171 abstained. The special-meeting Form 8-K reports the vote.

At closing, common and Class B shares received $19.00, Class C $6.34 and Class A preferred $10.50 under the merger terms. FONAR became wholly owned by Timothy Damadian-controlled FONAR, LLC; four directors resigned, and public price discovery ended.

What opportunities and risks matter after delisting?

FONAR’s opportunities are operational: more scans, faster throughput, new contracts, acquisitions and service of non-FONAR equipment. The trade-offs are reimbursement, collections, referrals, reduced disclosure and acquisition financing.

Where could growth come from?

Better utilization is the most practical growth driver. Shorter scans can increase studies without another scanner; Opus can extend service beyond FONAR equipment. New management contracts require less capital than owned centers but still demand careful credit underwriting.

Upright imaging can support referrals when symptoms change under weight or motion. Research, patents and software upgrades may keep the installed base relevant despite limited new-system sales.

Which constraints can weaken cash generation?

The definitive merger proxy explains public-company costs, IT remediation, acquisition financing and management’s private-structure rationale. Reduced reporting was an objective, creating a direct transparency trade-off.

What is the key takeaway for valuation and research?

FONAR is best analyzed as a healthcare-services company with a niche MRI asset, not a pure scanner manufacturer. Management and patient services drove earnings; equipment supplied differentiation but lost money. Delisting removed the public price, not the underlying valuation logic.

Which DCF drivers matter most now?

The $19.00 merger price is a transaction outcome, not a continuing quote. It represented premiums of 29.6% to the December 29, 2025 unaffected close, 21.9% to the July 8, 2025 close and 39.7% to the 90-day average ending June 30, 2025. Deal premiums do not replace operating forecasts.